Somatostatin and Alzheimer's disease

[1]  F. LaFerla,et al.  Aβ inhibits the proteasome and enhances amyloid and tau accumulation , 2008, Neurobiology of Aging.

[2]  Mark Rogers,et al.  NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? , 2007, Trends in pharmacological sciences.

[3]  J. Argente,et al.  17β-Estradiol protects depletion of rat temporal cortex somatostatinergic system by β-amyloid , 2007, Neurobiology of Aging.

[4]  N. Nalivaeva,et al.  New Insights into the Roles of Metalloproteinases in Neurodegeneration and Neuroprotection , 2007, International Review of Neurobiology.

[5]  V. Bonavita,et al.  Neurodegeneration and Alzheimer’s disease: the lesson from tauopathies , 2007, Neurological Sciences.

[6]  J. F. López-Téllez,et al.  Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1×APP transgenic model of Alzheimer's disease , 2006, Neurobiology of Aging.

[7]  C. Almeida,et al.  β-Amyloid Accumulation Impairs Multivesicular Body Sorting by Inhibiting the Ubiquitin-Proteasome System , 2006, The Journal of Neuroscience.

[8]  U. Kumar.  Expression of somatostatin receptor subtypes (SSTR1–5) in Alzheimer’s disease brain: An immunohistochemical analysis , 2005, Neuroscience.

[9]  A. Hervás-Aguilar,et al.  Effects of single and continuous administration of amyloid β-peptide (25–35) on adenylyl cyclase activity and the somatostatinergic system in the rat frontal and parietal cortex , 2005, Neuroscience.

[10]  I. Mook‐Jung,et al.  Amyloid peptide attenuates the proteasome activity in neuronal cells , 2005, Mechanisms of Ageing and Development.

[11]  M. Higuchi,et al.  Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation , 2005, Nature Medicine.

[12]  V. Barrios,et al.  Protective effects of insulin‐like growth factor‐I on the somatostatinergic system in the temporal cortex of β‐amyloid‐treated rats , 2005, Journal of neurochemistry.

[13]  C. Cotman,et al.  The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology , 2005, Journal of neuropathology and experimental neurology.

[14]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[15]  W. Meyerhof,et al.  Regulation and function of somatostatin receptors , 2004, Journal of neurochemistry.

[16]  Rémi Quirion,et al.  Comparative signaling pathways of insulin‐like growth factor‐1 and brain‐derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival , 2004, Journal of neurochemistry.

[17]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[18]  S. Lipton.  Turning down, but not off , 2004, Nature.

[19]  J. Lucas,et al.  Testing the ubiquitin–proteasome hypothesis of neurodegeneration in vivo , 2004, Trends in Neurosciences.

[20]  J. Ryder,et al.  Akt/GSK3beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. , 2004, Cellular signalling.

[21]  H. Mizukami,et al.  Presynaptic Localization of Neprilysin Contributes to Efficient Clearance of Amyloid-β Peptide in Mouse Brain , 2004, The Journal of Neuroscience.

[22]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[23]  J. Fastbom,et al.  G-protein &agr;-subunit levels in hippocampus and entorhinal cortex of brains staged for Alzheimer's disease neurofibrillary and amyloid pathologies , 2003, Neuroreport.

[24]  M. Onufriev,et al.  Single intracerebroventricular administration of amyloid-beta (25–35) peptide induces impairment in short-term rather than long-term memory in rats , 2003, Brain Research Bulletin.

[25]  A. Bush.  Copper, zinc, and the metallobiology of Alzheimer disease. , 2003, Alzheimer disease and associated disorders.

[26]  Mark P Mattson,et al.  Alzheimer's Presenilin 1 Mutations Impair Kinesin-Based Axonal Transport , 2003, The Journal of Neuroscience.

[27]  M. Robin,et al.  Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells , 2003, The Journal of cell biology.

[28]  George Perry,et al.  Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. , 2003, Biochemistry.

[29]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Gómez-Isla,et al.  Serum insulin-like growth factor I regulates brain amyloid-β levels , 2002, Nature Medicine.

[31]  T. Saido,et al.  Region‐specific reduction of Aβ‐degrading endopeptidase, neprilysin, in mouse hippocampus upon aging , 2002, Journal of neuroscience research.

[32]  T. Kubo,et al.  In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients , 2002 .

[33]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[34]  M. Duchen,et al.  β-Amyloid Fragment 25–35 Causes Mitochondrial Dysfunction in Primary Cortical Neurons , 2002, Neurobiology of Disease.

[35]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[36]  R. Sunahara,et al.  Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. , 2002, Molecular interventions.

[37]  Xiantao Wang,et al.  Signaling Events in Amyloid β-Peptide-induced Neuronal Death and Insulin-like Growth Factor I Protection* , 2002, The Journal of Biological Chemistry.

[38]  L. Goldstein,et al.  Kinesin-mediated axonal transport of a membrane compartment containing β-secretase and presenilin-1 requires APP , 2001, Nature.

[39]  K. Blennow,et al.  Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia , 2001, Peptides.

[40]  K. Shimoke,et al.  Differences in survival‐promoting effects and intracellular signaling properties of BDNF and IGF‐1 in cultured cerebral cortical neurons , 2001, Journal of neurochemistry.

[41]  C. Eckman,et al.  Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme* , 2001, The Journal of Biological Chemistry.

[42]  T. Iwatsubo,et al.  Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* , 2001, The Journal of Biological Chemistry.

[43]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[44]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[45]  R. Osamura,et al.  Characterization of 5'-flanking region of rat somatostatin receptor sst2 gene: transcriptional regulatory elements and activation by Pitx1 and estrogen. , 2001, Endocrinology.

[46]  S. Kawashima,et al.  Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. , 2001, European journal of pharmacology.

[47]  P. Mcgeer,et al.  Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide , 2001, Neuroscience Letters.

[48]  P. Riederer,et al.  Hippocampal level of neural specific adenylyl cyclase type I is decreased in Alzheimer's disease. , 2000, Biochimica et biophysica acta.

[49]  J. Kraus,et al.  Gene structure and regulation of the somatostatin receptor type 2 , 2000, Journal of Physiology-Paris.

[50]  Yuzuru Ito,et al.  Activation of caspase-9 and -3 during H2O2-induced apoptosis of PC12 cells independent of ceramide formation , 2000, Neurological research.

[51]  T. Saido,et al.  Reply to: 'Clearance of amyloid β-peptide from brain: transport or metabolism?' , 2000, Nature Medicine.

[52]  A. Nunomura,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[53]  I. Torres-Aleman,et al.  Circulating Insulin-Like Growth Factor I Mediates Effects of Exercise on the Brain , 2000, The Journal of Neuroscience.

[54]  S. Rabacchi,et al.  Caspase-2 Mediates Neuronal Cell Death Induced by β-Amyloid , 2000, The Journal of Neuroscience.

[55]  T. Saido,et al.  Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition , 2000, Nature Medicine.

[56]  Junying Yuan,et al.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β , 2000, Nature.

[57]  F. Tang,et al.  Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of β-amyloid (1-40) , 1999, Brain Research Bulletin.

[58]  C. Cotman,et al.  Neuronal Apoptosis Induced by β-Amyloid Is Mediated by Caspase-8 , 1999, Neurobiology of Disease.

[59]  J. Harada,et al.  Activation of caspase-3 in β-amyloid-induced apoptosis of cultured rat cortical neurons , 1999, Brain Research.

[60]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[61]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[62]  M. Weiner,et al.  WHAT DEPRESSIVE SYMPTOMS ARE REPORTED IN ALZHEIMER'S PATIENTS? , 1997, International journal of geriatric psychiatry.

[63]  S. Doré,et al.  Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. Jordán,et al.  Role of Calpain‐ and Interleukin‐1β Converting Enzyme‐Like Proteases in the β‐Amyloid‐Induced Death of Rat Hippocampal Neurons in Culture , 1997 .

[65]  V. Locatelli,et al.  Effects of GH and IGF-I administration on GHRH and somatostatin mRNA levels: I a study on ad libitum fed and starved adult male rats , 1997, Journal of endocrinological investigation.

[66]  G. Gillies.  Somatostatin: the neuroendocrine story. , 1997, Trends in pharmacological sciences.

[67]  W F Stewart,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.

[68]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[69]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[70]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[71]  J. Hauw,et al.  Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease , 1995, Neurobiology of Aging.

[72]  W. V. Van Nostrand,et al.  Amyloid β-Protein Inhibits Ubiquitin-dependent Protein Degradation in Vitro(*) , 1995, The Journal of Biological Chemistry.

[73]  H. Niznik,et al.  The somatostatin receptor family. , 1995, Life sciences.

[74]  P. Klivényi,et al.  Somatostatin and Alzheimer's disease. , 1995, Archives of gerontology and geriatrics.

[75]  Y. Patel,et al.  Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. , 1994, Life sciences.

[76]  R. Reinhardt,et al.  Insulin-like growth factors cross the blood-brain barrier. , 1994, Endocrinology.

[77]  B. Winblad,et al.  Regionally selective alterations in G protein subunit levels in the Alzheimer's disease brain , 1994, Brain Research.

[78]  C. Nemeroff,et al.  CSF somatostatin in Alzheimer's disease and major depression: Relationship to hypothalamic-pituitary-adrenal axis and clinical measures , 1993, Psychoneuroendocrinology.

[79]  G. Vogt,et al.  The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ m coupling efficiency to adenylate cyclase and in agonist‐induced receptor desensitization , 1993, FEBS letters.

[80]  C. Masters,et al.  A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. , 1993, The Journal of biological chemistry.

[81]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[82]  V. Höllt,et al.  Cloning and expression of a novel mouse somatostatin receptor (SSTR2B) , 1992, FEBS letters.

[83]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[84]  B. Winblad,et al.  Adenylyl Cyclase Activity in Postmortem Human Brain: Evidence of Altered G Protein Mediation in Alzheimer's Disease , 1992, Journal of neurochemistry.

[85]  R. Quirion,et al.  Deficits in the somatostatin SS1 receptor sub-type in frontal and temporal cortices in Alzheimer's disease , 1992, Brain Research.

[86]  D. Selkoe,et al.  Amyloid protein and Alzheimer's disease. , 1991, Scientific American.

[87]  B. Winblad,et al.  Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain , 1991, Journal of the Neurological Sciences.

[88]  J. Bohl,et al.  Reduced basal and stimulated (isoprenaline, Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated with histopathological changes , 1991, Brain Research.

[89]  L. Siever,et al.  CSF Somatostatin in alzheimer's disease, depressed patients, and control subjects , 1988, Biological Psychiatry.

[90]  J. Edwardson,et al.  Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases , 1988, Journal of the Neurological Sciences.

[91]  Joseph B. Martin,et al.  Widespread reduction of somatostatin‐like immunoreactivity in the cerebral cortex in Alzheimer's disease , 1986, Annals of neurology.

[92]  M. Beal,et al.  Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. , 1985, Science.

[93]  T. Hökfelt,et al.  Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat , 1984, Neuroscience.

[94]  L. Vécsei,et al.  Phenoxybenzamine antagonizes somatostatin-induced antiamnesia in rats. , 1984, European journal of pharmacology.

[95]  R. Katzman.,et al.  Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa , 1980, Nature.

[96]  F. Suzuki,et al.  Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with alzheimer’s disease , 2008, Journal of Molecular Neuroscience.

[97]  T. Dawson,et al.  Role for the ubiquitin-proteasome system in Parkinson’s disease and other neurodegenerative brain amyloidoses , 2007, NeuroMolecular Medicine.

[98]  A. Henares.  Chronic but Not Acute Intracerebroventricular Administration of Amyloid b-Peptide(25-35) Decreases Somatostatin Content, Adenylate Cyclase Activity, Somatostatin-Induced Inhibition of Adenylate Cyclase Activity, and Adenylate Cyclase I Levels in the Rat Hippocampus , 2007 .

[99]  T. Saido,et al.  Etiology of sporadic Alzheimer’s disease: Somatostatin, neprilysin, and amyloid β peptide , 2005 .

[100]  P. Riederer,et al.  Ca2+/CaM-sensitive adenylyl cyclase activity is decreased in the Alzheimer's brain: Possible relation to type I adenylyl cyclase , 2005, Journal of Neural Transmission.

[101]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[102]  M. Duchen,et al.  Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. , 2002, Neurobiology of disease.

[103]  T. Gómez-Isla,et al.  Serum insulin-like growth factor I regulates brain amyloid-beta levels. , 2002, Nature medicine.

[104]  Nigel H. Greig,et al.  Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer’s disease , 2002, NeuroMolecular Medicine.

[105]  T. Nabeshima,et al.  Memory deficits and increased emotionality induced by β-amyloid (25–35) are correlated with the reduced acetylcholine release and altered phorbol dibutyrate binding in the hippocampus , 2001, Journal of Neural Transmission.

[106]  Xiaomin Wang,et al.  Cloning and expression of a novel mouse somatostatin receptor ( SSTR 2 B ) , 2001 .

[107]  R. Orlowski.  The role of the ubiquitin-proteasome pathway in apoptosis , 1999, Cell Death and Differentiation.

[108]  C. Nemeroff,et al.  Regional Neuropeptide Pathology in Alzheimer's Disease: Corticotropin-Releasing Factor and Somatostatin. , 1998, Journal of Alzheimer's disease : JAD.

[109]  R. Miller,et al.  Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture. , 1997, Journal of neurochemistry.

[110]  P. Dournaud,et al.  The neurobiology of somatostatin. , 1994, Critical reviews in neurobiology.

[111]  C. Nemeroff,et al.  SOMATOSTATIN: A NEUROPEPTIDE SYSTEM PATHOLOGICALLY ALTERED IN ALZHEIMER'S DISEASE AND DEPRESSION , 1992, Clinical neuropharmacology.

[112]  G. Bissette,et al.  Somatostatin in Alzheimer's disease and depression. , 1992, Life sciences.

[113]  M. Rodríguez-Arnao,et al.  Influence of somatostatin and growth hormone-releasing factor on behavior. Clinical and therapeutic implications in neuropsychiatric disorders. , 1988, Hormone research.

[114]  S. Reichlin.  Somatostatin (First of two parts) , 1983 .